OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology Communications is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Development and evaluation of a virtual reality driving test for patients with cirrhosis	221
Mesenchymal stem/stromal cells armored by FGF21 ameliorate alcohol-induced liver injury through modulating polarization of macrophages	164
A genetic variant in the CD40 gene is related to HBV infection in the Chinese Han population	140
HBV DNA polymerase regulates tumor cell glycogen to enhance the malignancy of HCC cells	101
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial	87
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?	85
Copper deficiency is an independent risk factor for mortality in patients with advanced liver disease	83
Association between widespread pain and associated symptoms in patients with cirrhosis	81
Pain in chronic liver disease compared to other chronic conditions: Results from a contemporary nationally representative cohort study	74
Issue Information	66
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials	64
Erratum: Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study	61
Co‐regulation of hepatic steatosis by ferritinophagy and unsaturated fatty acid supply	61
Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH	61
Reduced short-term survival following liver transplant in patients with acute-on-chronic liver failure: Reevaluating OPTN data	56
Pharmacist‐led educational interventions involving the “hidden” patient in cirrhosis—Caregivers	55
Patient‐oriented medication education intervention has long‐term benefits for people with decompensated cirrhosis	55
A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis	54
Zinc fingers and homeoboxes 2 is required for diethylnitrosamine‐induced liver tumor formation in C57BL/6 mice	54
Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda	53
Resolution of hepatic fibrosis after ZFN-mediated gene editing in the PiZ mouse model of human α1-antitrypsin deficiency	52
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants	52
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study	52
Depression and anxiety management in cirrhosis	51
Immunologic landscape of human hepatic hemangiomas and epithelioid hemangioendotheliomas	49

Granulomatous liver diseases	49
Increasing nonalcoholic fatty liver disease–related mortality rates in the United States from 1999 to 2022	46
Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease	45
Medical malpractice claims in Hepatology: Rates, Reasons, and Results	44
Complementary and alternative medicines and liver disease	44
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia	43
Disproportionate increases in alcohol-associated hepatitis incidence in women and individuals of low socioeconomic status: A population-based study using the Rochester epidemiology project database	42
A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary tract cancer	42
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis	42
COVID‐19 and the Uncovering of Health Care Disparities in the United States, United Kingdom and Canada: Call to Action	42
Visualizing in situ viral replication across the natural history of chronic HBV infection	41
Clinical decision support automates care gap detection among primary care patients with nonalcoholic fatty liver disease	41
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease	40
Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease	40
Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	39